Baranowska-Nowak Marta, IwaŃczak Barbara, Szczepanik Mariusz, Banasiuk Marcin, DembiŃski Łukasz, Karolewska-Bochenek Katarzyna, Dziekiewicz Marcin, Radzikowski Andrzej, Banaszkiewicz Aleksandra
Pediatric Hospital in Warsaw, Poland.
2nd Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw, Poland.
Cent Eur J Immunol. 2020;45(2):144-150. doi: 10.5114/ceji.2020.97902. Epub 2020 Jul 27.
To evaluate the immune response rate in children with inflammatory bowel disease (IBD) who received the full hepatitis B vaccination course in infancy. We also evaluated rates of response to booster doses.
Participants were 1- to 18-year-old children with IBD, who received 3 doses of the hepatitis B vaccine in infancy. The study subjects were on no immunosuppressive therapy, on immunomodulators, on biological therapy, or received combo therapy. Anti-hepatitis B surface antibody (anti-HBs) level ≥ 10 mIU/ml was considered to be seroprotective. Patients with anti-HBs level < 10 mIU/ml received 1 or 3 doses of hepatitis B vaccine, and their post-vaccination anti-HBs levels were evaluated.
In total, we included 157 subjects, with a median age of 14.5 years. Anti-HBs levels ≥ 10 mIU/ml were found in 84/157 (53.5%) patients and were not associated with age (p = 0.3), sex (p = 0.7), or IBD type (p = 0.9). There was no significant difference in the rate of seroconversion between IBD patients treated with no immunosuppressive drugs, immunomodulators, biologicals, and combo therapy (30.4% vs. 39.3% vs. 2.7% vs. 7.1%, respectively, p = 0.3). After the first and third dose of booster vaccine, anti-HBs levels ≥ 10 mIU/ml were as follows: 92% and 100%, respectively.
The immune response in children with IBD, who received the full series of hepatitis B vaccinations in infancy was inadequate and did not depend on the type of therapy. The booster dose(s) of vaccine could help to protect this group of patients from hepatitis B virus.
评估婴儿期接受全程乙型肝炎疫苗接种的炎症性肠病（IBD）患儿的免疫应答率。我们还评估了加强剂量的应答率。
研究对象为1至18岁的IBD患儿，这些患儿在婴儿期接受了3剂乙型肝炎疫苗接种。研究对象未接受免疫抑制治疗、接受免疫调节剂治疗、接受生物治疗或接受联合治疗。抗乙型肝炎表面抗体（抗-HBs）水平≥10 mIU/ml被认为具有血清保护作用。抗-HBs水平<10 mIU/ml的患者接受1剂或3剂乙型肝炎疫苗，并评估其接种疫苗后的抗-HBs水平。
我们共纳入157名受试者，中位年龄为14.5岁。84/157（53.5%）例患者的抗-HBs水平≥10 mIU/ml，且与年龄（p = 0.3）、性别（p = 0.7）或IBD类型（p = 0.9）无关。未接受免疫抑制药物、免疫调节剂、生物制剂和联合治疗的IBD患者之间的血清转化率无显著差异（分别为30.4%、39.3%、2.7%和7.1%，p = 0.3）。在第一剂和第三剂加强疫苗接种后，抗-HBs水平≥10 mIU/ml的比例分别为92%和100%。
婴儿期接受全程乙型肝炎疫苗接种的IBD患儿的免疫应答不足，且不依赖于治疗类型。疫苗加强剂量可帮助保护这组患者免受乙型肝炎病毒感染。
